The world's first long-term anti AIDS new drug has been approved for listing, and is independently developed by Chinese enterprises
-
Last Update: 2018-06-05
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Source: Sina Pharmaceutical Co., Ltd (hereinafter referred to as "frontier bio") learned from frontier bio Pharmaceutical (Nanjing) Co., Ltd (hereinafter referred to as "frontier bio") on June 4, 2018 that its independently developed national first-class new drug iconine (ibovetai for injection) was approved for listing by the state drug administration Iconine is the world's first long-term anti AIDS fusion inhibitor, which is independently researched and developed by cutting-edge biology and has global original intellectual property rights AIDS is a major infectious disease in the field of public health Through the spread of HIV, the number of people infected in China is still increasing every year However, there is a lack of drugs to treat AIDS, and there are major clinical needs to be met Iconine is a new long-acting HIV-1 fusion inhibitor, which is approved to be used in combination with other antiretroviral drugs to treat HIV-1 infected patients who still have virus replication after antiviral treatment According to the mid-term data analysis of the clinical phase III trial, once a week, the combination of iconin and lopinavir / ritonavir is used to treat HIV with "failure of first-line Formula treatment" The therapeutic effect of "infected person" was equal to or better than the second-line formula (three drug combination, control group) recommended by the World Health Organization (who), and showed statistically better renal safety compared with the control group containing tenofovir Aikonin has a new molecular mechanism of action, which is effective for HIV-1 virus and drug-resistant virus It has the unique advantages of low drug frequency (once a week), high drug-resistant barrier, high safety, small side effects, etc., which can significantly improve patients' drug compliance and improve their quality of life "After 16 years of R & D, more than 150 researches have been carried out by iconine, which has been continuously supported by the major new drug creation projects of the 11th five year plan, the 12th Five Year Plan and the 13th five year plan." Dr Xie Dong, chairman and chief scientist of cutting edge biology, said, "aikoning is the first independent innovative drug in the field of AIDS in China, providing new treatment options for the majority of HIV infected people, hoping to break the lack of new and good drugs for AIDS treatment in China, truly benefit patients and save lives."
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.